Camfetamine

{{Short description|Chemical compound}}

{{Use dmy dates|date=January 2014}}

{{Drugbox

| IUPAC_name = N-methyl-3-phenylbicyclo[2.2.1]heptan-2-amine

| image = Camfetamine.svg

| width = 160

| tradename =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number = 92499-19-9

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = 3E7N2GO76U

| ATC_prefix = none

| ATC_suffix =

| ATC_supplemental =

| PubChem =

| ChemSpiderID = 26608747

| chemical_formula =

| C=14 | H=19 | N=1

| smiles = C2CC1CC2C(NC)C1c3ccccc3

| StdInChI = 1S/C14H19N/c1-15-14-12-8-7-11(9-12)13(14)10-5-3-2-4-6-10/h2-6,11-15H,7-9H2,1H3

| StdInChIKey = CTVMYAZECFXZLN-UHFFFAOYSA-N

}}

Camfetamine (N-methyl-3-phenyl-norbornan-2-amine) is a stimulant drug closely related to the appetite suppressant fencamfamine, being its N-methyl homologue.{{ cite patent | country = DE | status = patent | inventor = Thesing J, Seitz G, Hotovy R, Sommer S | title = Verfahren zur Herstellung analeptisch wirksamer N-substituierter Aminonorcamphanderivate bzw. von deren Säureadditionssalzen und quaternären Ammoniumverbindungen | number = 1110159 | gdate = 1961-07-06 | assign1 = E. Merck AG }} It has been sold as a designer drug following the banning of mephedrone and related substituted cathinone derivatives in many countries,{{cite journal | vauthors = Kavanagh P, Angelov D, O'Brien J, Power JD, McDermott SD, Talbot B, Fox J, O'Donnell C, Christie R | display-authors = 6 | title = The synthesis and characterization N-methyl-3-phenyl-norbornan-2-amine (Camfetamine™) | journal = Drug Testing and Analysis | volume = 5 | issue = 4 | pages = 247–53 | date = April 2013 | pmid = 22374810 | doi = 10.1002/dta.411 }} and reportedly has slightly stronger stimulant effects than fencamfamine, but with correspondingly more severe side effects.